Stay updated with breaking news from Formycon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a total of €77.7 million, according to its annual earnings report. ....
On Friday, January 20, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") filed an ex parte application for a scheduling order setting the schedule for preliminary injunction proceedings or, in the alternative, an emergency status conference. ....
EQSAdhoc Formycon AG Key word Corporate ActionCapital Increase Formycon resolves on cash capital increase of EUR 8284 million – all new shares were subscribed by Gedeon Richter as new strategic inves ....
According to PWC, "2023 was a reasonably strong year for the pharmaceutical and life sciences sector with both deal value and volume of M&A close to pre-pandemic levels." ....
It has been reported that Celltrion has finalized a settlement with Johnson & Johnson ("J&J") in the United States relating to CT-P43, Celltrion's ustekinumab biosimilar to J&J's STELARA®. ....